News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals, Inc. (INFI)'s IPI-504 Named One of Windhover Information Inc. and Campbell Alliance's "Top 10 Projects to Watch" in Oncology



11/17/2009 9:07:45 AM

CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES